The Phase II CT of RUTI®, the therapeutic vaccine against TB, published!

Dr Cardona and the other members of the team involved in the Phase II CT of the therapeutic vaccine RUTI® have published the results of the study registered in ClinicalTrials.gov as NCT01136161

Conducted in SouthAfrica, the aim of the study was to evaluate the safety, tolerability and immunogenicity of three different doses (5, 25 and 50 µg) of RUTI® compared to placebo in subjects (HIV+ and HIV-) with latent tuberculosis infection.

The double-blind, randomized, placebo-controlled CT demonstrated the tolerability of RUTI® in infected subjects.The immunogenicity profile of RUTI vaccine in LTBI subjects suggested considering one single injection of one of the highest doses in future trials.

This has been another important step in the clinical development of RUTI® towards commercialization, a vaccine which was designed, patented and initially developed in our Unit by the leadership of Dr Cardona, who was its inventor. The development was further transfered to a spin-off company specifically created to accomplish this objective, Archivel Farma SL).In this sense, the relationship with this company has led to personnel (students) training, generation of thesis works, manuscripts and patents in collaboration, and a profitable transfer of knowledge. The company is now seeking funding to complete the clinical development of the vaccine with the aim to arrive to the market.

You can read the paper here

Advertisements
This entry was posted in Uncategorized and tagged , , , , , , , , . Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s